MYO earnings analysis
What we found in MYO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Myomo reported Q1 2026 revenue of $10.1 million, a 3% increase year-over-year, surpassing estimates by 9.3%. EPS came in at $(0.07), beating the estimate of $(0.12) and reflecting reduced net losses compared to the previous period. Management anticipates revenue growth in Q2, backed by increased patient referrals and productivity in the O&P channel.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beats Estimates
- Actual revenue of $10.1 million exceeded estimates by 9.3% ($925,184).
- Improved EPS Performance
- EPS of $(0.07) surpassed the estimate of $(0.12), showing a positive surprise of 41.67%.
- Gross Margin Growth
- Gross margin increased to 68.2%, up from 67.2% YoY due to lower material costs.
- Segment Growth in International Sales
- International revenue grew to $2.0 million, a rise from $1.3 million in Q1 2025.
- Reduced Operating Cash Flow Loss
- Net cash used in operating activities improved to $(2.2) million from $(2.7) million YoY.
- Continued Debt Management
- A term loan of $17.5 million was secured, with the first tranche of $12.5 million utilized to repay previous debts.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Dependence on Medicare
- The business relies heavily on Medicare reimbursement, which poses risks if policies change.
- Increased Competition in O&P Channel
- Growing competitors in the orthopedic and prosthetics market could pressure market share.
- Potential Import Tariffs Impact
- Tariffs on imports are estimated to impact gross margin by less than 1%, posing a risk as tariffs could escalate.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.07
- Gross margin
- 68.2%
- Segment
- Direct billing: $7.17 million
- Segment
- International: $2.01 million
- Segment
- U.S. O&P: $0.84 million
- Segment
- VA: $0.096 million
What they said about what is next.
Management expects Q2 2026 revenue between $10.3 million and $10.8 million.
The filing reads better than the one before it.
What came before.
- 10-K · April 29, 2026
- Myomo reported a revenue of $11.35 million for Q4 2025, exceeding estimates by 10.21%. However, it recorded a GAAP EPS loss of $(0.09), consistent with consensus expectations. Notably, its gross margin improved to…
- 10-K · March 9, 2026
- Myomo positions itself as the market leader in myoelectric limb orthotics with a clear product roadmap (MyoPro2x released April 2025; MyoPro3 and pediatric MyoPal planned). Q4 2025 revenue beat at $11,353,000 with a…
- 10-Q · May 7, 2025
- Myomo reported Q1 product revenue of $9,831,814 (vs $3,754,389 in Q1 2024) and GAAP net loss of $3,465,058, or $(0.08) per share. Gross margin improved to 67.2% while operating margin remained negative at -35.8%;…
- 10-K · March 10, 2025
- Myomo’s 10-K emphasizes a focused strategy to be the market leader in myoelectric limb orthotics (the MyoPro line) with a product roadmap that includes MyoPro3 and a pediatric MyoPal. The filing highlights durable…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MYO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever